M1403 – Patients with baseline and follow-up promis surveys documented in the medical record
HCPCS Level II code · M codes: Medical Services and Quality Measures
HCPCS codeM1403
- Long description
- Patients with baseline and follow-up promis surveys documented in the medical record
- Short description
- Bslne and fu promis doc
- Pricing indicator
00Not separately priced by Part B (bundled, not covered or Part A only)- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
Z2Undefined codes- Added
- January 1, 2025
- Last change
- January 1, 2025 – No change
Frequently asked questions
What is HCPCS code M1403?
M1403 is a HCPCS Level II code for patients with baseline and follow-up promis surveys documented in the medical record.
Does Medicare cover M1403?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby M codes
- M1395 – Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1396 – Patients on a therapeutic clinical trial
- M1397 – Patients with recurrence/disease progression
- M1398 – Patients with baseline and follow-up promis surveys documented in the medical record
- M1399 – Patients who leave the practice during the follow-up period
- M1400 – Patients who died during the follow-up period
- M1401 – Stages i-iii breast cancer
- M1402 – Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1404 – Patients on a therapeutic clinical trial
- M1405 – Patients with recurrence/disease progression
- M1406 – Patients who leave the practice during the follow-up period
- M1407 – Patients who died during the follow-up period
- M1408 – Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409 – Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410 – Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411 – Currently on first-line immune checkpoint inhibitors without chemotherapy
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.